title: Body mass index and body composition in adolescents treated with gonadotropin-releasing hormone analogue triptorelin depot for central precocious puberty: data at near final height.
abstract: OBJECTIVE
  In children with central precocious puberty (CPP), gonadotropin-releasing hormone (GnRH) analogue treatment has been associated with an increase in body mass index (BMI). We evaluated BMI and body composition in adolescents treated with GnRH analogue at their near final height to assess the long-term effects of therapy on these parameters.
  
  
  METHODS
  We studied 20 patients (14.8 +/- 1.6 years; 17 females) previously treated with triptorelin depot for CPP (3.75 mg/28 days) from 8.1 +/- 0.8 to 11.5 +/- 0.8 years. 23 healthy adolescents with normal onset of puberty (14.7 +/- 2.1 years, 19 females) were the controls. BMI and body composition (dual-energy x-ray absorptiometry) were assessed.
  
  
  RESULTS
  Patients reached their near adult height (-0.5 +/- 1.1 standard deviation score (SDS)); the girls were menstruating and the majority (15/17) had regular cycles, the boys showed normal testicular function. BMI was unchanged from the start of GnRH analogue therapy (0.4 +/- 1.0 SDS) to near adult height (0.2 +/- 1.0 SDS, p = NS vs. 0). Total fat mass (TFM) was significantly increased (16,144 +/- 8,065 g; controls 10,712.1 +/- 4,120.4 g, p < 0.02); glucose homeostasis and lipid profile corresponded to reference ranges.
  
  
  CONCLUSIONS
  GnRH analogue therapy did not show long-term detrimental effects on BMI, but it may increase TFM, suggesting that body composition should be monitored till adulthood.
authors.affiliation: Adolescent Medicine, II Pediatric Division, Department of Obstetrics, Gynecology and Pediatrics, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.
authors.forename: Elena
authors.initials: E
authors.lastname: Chiocca
authors.forename: Eleonora
authors.initials: E
authors.lastname: Dati
authors.forename: Giampiero I
authors.initials: GI
authors.lastname: Baroncelli
authors.forename: Stefano
authors.initials: S
authors.lastname: Mora
authors.forename: Donatella
authors.initials: D
authors.lastname: Parrini
authors.forename: Paola
authors.initials: P
authors.lastname: Erba
authors.forename: Silvano
authors.initials: S
authors.lastname: Bertelloni
mesh_terms: D000293:Adolescent; D001823:Body Composition / Q000187:drug effects* / Q000502:physiology; D001827:Body Height / Q000187:drug effects* / Q000502:physiology; D015992:Body Mass Index; D003692:Delayed-Action Preparations; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000008:administration & dosage* / Q000031:analogs & derivatives; D006801:Humans; D008297:Male; D011629:Puberty, Precocious / Q000188:drug therapy* / Q000503:physiopathology; D016896:Treatment Outcome; D017329:Triptorelin Pamoate / Q000008:administration & dosage*
chemical_list: D003692:Delayed-Action Preparations; D017329:Triptorelin Pamoate; D007987:Gonadotropin-Releasing Hormone